isbscience.org/research/brain-health/
ISB, along with a collaborative network of partners, is pioneering a multimodal approach that combines personal data, lifestyle factors, cognitive training and systems medicine — and is rigorously testing these new approaches in clinical trials. This approach is critical to prevent, slow, and even reverse many neurological conditions before they become irreversible.
Every single clinical trial created to test Alzheimer’s disease drugs have failed.
Many neurological conditions are difficult, if not impossible, to cure. This is especially true in the late stages of disease.
Alzheimer’s disease is one such debilitating condition that currently has no cure, and has stymied researchers at every turn.
Prevention and early detection are crucial to identify these conditions at the earliest possible stage.
The greatest hope for reversing and preventing Alzheimer’s disease and other neurological disorders is a multimodal approach that combines diet, exercise, drug treatment, coaching, brain training and other personalized treatments.
Observational studies suggest this novel approach can slow, stop, and in some cases reverse Alzheimer’s disease progression. ISB is collaborating on research to expand our understanding of the causes, effects and treatment of significant impairment of the human brain.
The recently completed, ISB-led Coaching for Cognition in Alzheimer’s (COCOA) trial shows that diet and exercise can help people suffering from dementia. Senior Research Scientist Dr. Jared Roach discussed the findings in a Research Roundtable presentation.
We need your help to realize the full potential of multimodal therapy to slow, stop or reverse Alzheimer’s disease. A donation from you will help ensure that this critical research becomes a cornerstone of our brain health platform with the goal of positively impacting the standard of care for Alzheimer’s patients.
Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.
In their new book, “The Age of Scientific Wellness: Why the Future of Medicine is Personalized, Predictive, Data-Rich, and In Your Hands,” Drs. Lee Hood and Nathan Price introduce a new way of thinking about healthcare – a focus on preventing diseases and optimizing overall wellness.
There is tremendous market and media frenzy around new Alzheimer’s disease drugs, but their efficacy is contested while the potential of prevention is untapped and underreported, Drs. Lee Hood and Nathan Price wrote in an opinion piece published by the Los Angeles Times.
